Multi-center, Double-blind, Randomized, Placebo-controlled Study of Selective 11 Beta-HSD1 Inhibition With RO5093151 for 12 Weeks to Investigate Efficacy, Safety and Pharmacokinetics of RO5093151 in Non-alcoholic Fatty Liver Disease and Its Metabolic Consequences
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs RG 4929 (Primary)
- Indications Insulin resistance; Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Roche
- 06 Jul 2012 Actual end date (June 2012) added as reported by ClinicalTrials.gov.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed.
- 18 Apr 2012 Actual patient number changed from 83 to 82 as reported by ClinicalTrials.gov.